

To,
BSE Limited
Scrip Code: 542650

National Stock Exchange of India Ltd
Scrip Symbol: METROPOLIS

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information in terms of Regulation 8 of the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has provided a business update for the quarter ended September 30, 2024.

This update seeks to provide an overall summary of the operating performance and demand trends witnessed during the quarter ended September 30, 2024. A detailed information update will follow once the Board of Directors approves the financial results for Q2FY25.

The Company has been able to deliver strong results in Q2FY25 driven by a combination of increased volumes, product mix change and realizations benefits. Continued momentum from its Truhealth packages, along with successful upselling of bundled packages, led to higher test per patient, contributing to overall revenue growth.

Margins for Q2FY25 have expanded on a sequential basis in line with commentary provided earlier. The Company continues to see a gradual uptick in margins on account of operating leverage, cost optimization and growing contribution from its ongoing network expansion.

Please find below key highlights of Q2FY25:

- Revenues grew by ~13% on a Y-o-Y basis.
- Revenue growth was driven by patient volume growth, test volume growth and change in product mix coupled with realization benefits.
- B2C revenues grew at ~20% on a Y-o-Y basis on account of industry-leading testing capabilities and strong brand appeal among end consumers.
- Truhealth wellness and bundling segment is the fastest-growing segment.
- Company has added 6 labs and 120 centers in Q2FY25 and increased the presence to a total of ~700 towns in Q2FY25 compared to ~650 towns in FY24.
- Company is debt free with cash reserves in excess of INR 180 crores as on September 30, 2024.

The quarterly business update is on a consolidated basis. The financial results of Q2FY25 is subject to review by Auditors.

Thanking you,
Yours faithfully,

For **Metropolis Healthcare Limited**

Kamlesh C Kulkarni
Head – Legal & Secretarial

BLOOD TESTS • DIAGNOSTICS • WELLNESS

METROPOLIS
The Pathology Specialist

Metropolis Healthcare Limited

Registered Office: 4th Floor, East Wing, Plot-254 B, Nirlon House, Dr. Annie Besant Road, Worli, Mumbai - 400030, Maharashtra, India.

Corporate Office & Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

CIN: L73100MH2000PLC192798 Tel No.: 8422 801 801 Email: support@metropolisindia.com

Website: www.metropolisindia.com